Nicola MD - Aeterna Zentaris Chief Development
| AEZSDelisted Stock | USD 6.14 0.08 1.29% |
Executive
Nicola MD is Chief Development of Aeterna Zentaris
| Phone | 843 900 3223 |
| Web | https://www.zentaris.com |
Aeterna Zentaris Management Efficiency
The company has return on total asset (ROA) of (0.2996) % which means that it has lost $0.2996 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8171) %, meaning that it created substantial loss on money invested by shareholders. Aeterna Zentaris' management efficiency ratios could be used to measure how well Aeterna Zentaris manages its routine affairs as well as how well it operates its assets and liabilities.Aeterna Zentaris currently holds 277.57 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Aeterna Zentaris has a current ratio of 9.66, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Aeterna Zentaris' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MBA Ashizawa | Bio Path Holdings | N/A | |
| David JD | Pulmatrix | 66 | |
| Calais Pharm | Transcode Therapeutics | 65 | |
| Gregory MD | Tonix Pharmaceuticals Holding | 58 | |
| Kristi Sarno | Ibio Inc | N/A | |
| Anthony Price | Bio Path Holdings | N/A | |
| Catherine Collis | Jaguar Animal Health | N/A | |
| Andrew Taubman | Adial Pharmaceuticals | N/A | |
| Darryl Rideout | Tonix Pharmaceuticals Holding | N/A | |
| RN MBA | Transcode Therapeutics | N/A | |
| MBA MBA | Bio Path Holdings | N/A | |
| MD FACP | Moleculin Biotech | 72 | |
| Dr MBA | Tonix Pharmaceuticals Holding | 66 | |
| Felipe Duran | Ibio Inc | 45 | |
| Dr D | Aditxt Inc | N/A | |
| Daniel MD | Transcode Therapeutics | 72 | |
| MPH MD | Tonix Pharmaceuticals Holding | N/A | |
| MS MD | Aditxt Inc | N/A | |
| Carol MBA | Jaguar Animal Health | 60 | |
| Dolly Tyan | Aditxt Inc | N/A | |
| John JD | Adial Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.82 | |||
| Return On Asset | -0.3 |
Aeterna Zentaris Leadership Team
Elected by the shareholders, the Aeterna Zentaris' board of directors comprises two types of representatives: Aeterna Zentaris inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aeterna. The board's role is to monitor Aeterna Zentaris' management team and ensure that shareholders' interests are well served. Aeterna Zentaris' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aeterna Zentaris' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Klaus Paulini, CEO President | ||
| Amlie Mtivier, Assistant Sec | ||
| Eckhard Guenther, Sr Germany | ||
| ICDD MBA, CEO President | ||
| Giuliano Fratta, Senior CFO | ||
| Matthias Gerlach, Senior Production | ||
| Nicola MD, Chief Development | ||
| Michael Teifel, Vice President - Non-Clinical Sciences |
Aeterna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aeterna Zentaris a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.82 | |||
| Return On Asset | -0.3 | |||
| Current Valuation | 15.15 M | |||
| Shares Outstanding | 3.06 M | |||
| Shares Owned By Insiders | 1.32 % | |||
| Shares Owned By Institutions | 5.21 % | |||
| Number Of Shares Shorted | 5.27 K | |||
| Price To Earning | 15.42 X | |||
| Price To Book | 0.88 X | |||
| Price To Sales | 7.60 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Aeterna Stock
If you are still planning to invest in Aeterna Zentaris check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeterna Zentaris' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |